Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).

Primary tabs

field_vote: 
Average: 7 (1 vote)
Publication type: 
Therapeutic Substance(s): 
References: 

Crit Rev Oncol Hematol. 2006 Jul;59(1):40-50. Epub 2006 Apr 4.

Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).
 
de Castro Junior G, Puglisi F, de Azambuja E, El Saghir NS, Awada A.

Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium.
Angiogenesis
plays a crucial role in facilitating tumor growth and the metastatic
process, and it is the result of a dynamic balance between
pro-angiogenic factors, like vascular endothelial growth factor (VEGF)
and platelet-derived growth factor, and antiangiogenic factors, like
thrombospondin-1 and angiostatin. Many drugs that target human tumors,
like bevacizumab and some VEGF-receptor tyrosine-kinase inhibitors
(e.g., BAY 43-9006, SU11248 and PTK787/ZK222584) have been studied in
clinical trials, with favorable toxicity reports and encouraging
results in advanced colorectal cancer, renal cell cancer, breast cancer
and non-squamous non-small cell lung cancer, either combined with
chemotherapy, or in monotherapy. Another potential approach to
inhibiting angiogenesis is through metronomic chemotherapy (low doses
of chemotherapy for long periods of time). This review describes the
mechanisms of the angiogenic process and evaluates the recent data
about antiangiogenic therapies in clinical trials.